Low-pH Antibody Composition for High-Concentration Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein-based pharmaceuticals, particularly bispecific T cell engaging antibody constructs, face challenges with protein instability, including aggregation and degradation during manufacturing, storage, and administration, which affect their efficacy and safety.
Innovation Solution
A pharmaceutical composition comprising an antibody construct with specific isoelectric points for its domains, combined with a pH range of 3.5 to 6, buffer agents, saccharides, and surfactants, stabilizes the antibody by promoting electrostatic repulsion and reducing aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibody constructs are formulated at higher concentrations to improve therapeutic efficacy, then treatment effectiveness increases, but protein aggregation increases and stability decreases
Solution Approach 1:
The patent applies parameter changes by adjusting the pH to a specific range (3.5-6.0) where electrostatic repulsion between antibody molecules is maximized. This pH optimization prevents aggregation even at high concentrations (up to 100 mg/mL), resolving the contradiction between concentration and stability. The buffer system maintains this critical pH parameter throughout storage and administration.
Solution Approach 2:
The patent introduces buffer agents and surfactants as intermediary substances that mediate between antibody molecules. These intermediaries create a protective environment that prevents direct protein-protein interactions leading to aggregation, allowing high concentrations to be maintained without stability loss.
2Stability of the object's composition
If conventional protein formulations are used to maintain stability, then protein degradation is reduced, but lyophilization is required which complicates administration
Solution Approach 1:
The patent changes the formulation parameters by using a low pH buffer system (pH 3.5-6.0) with specific excipients that enable liquid stability without lyophilization. This parameter optimization allows the protein to remain stable in liquid form at various temperatures including room temperature, eliminating the need for freeze-drying and complex reconstitution procedures.
Solution Approach 2:
The patent converts the typically harmful low pH condition into a beneficial state by optimizing the formulation at pH 3.5-6.0. This low pH environment actually enhances stability by increasing electrostatic repulsion between molecules, while also enabling liquid formulation. The initially problematic acidic condition becomes the key to achieving both stability and administration convenience.
3Stability of the object's composition
If pH is lowered to enhance electrostatic repulsion and reduce aggregation, then protein stability improves, but potential immunogenicity increases
Solution Approach 1:
The patent optimizes the pH parameter within a specific range (3.5-6.0) that balances electrostatic repulsion benefits with immunogenicity concerns. This precise parameter control maximizes aggregation prevention while maintaining pH levels that are acceptable for parenteral administration. The buffer system ensures pH remains within this optimal window.
Solution Approach 2:
The patent introduces buffer agents and surfactants as intermediary substances that mitigate the potential harmful effects of low pH. These intermediaries protect the protein from excessive acid exposure while maintaining the electrostatic repulsion benefits, thereby reducing immunogenicity risk associated with acidic formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enhances the stability of bispecific antibody constructs, allowing for higher concentrations and reduced aggregation, even at accelerated temperatures, and supports convenient administration without the need for lyophilization.
Implementation Method 1
The pH of the pharmaceutical composition is in the range of 3.5 to 6, wherein the low pH promotes stability and reduces aggregation of the antibody construct
Data Source
AI summary
The present invention provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.